Following successful work in the areas of diabetes, chronic pain, inflammation and neurological disorders, Frost & Sullivan is seeking partner companies for a new end-user study on preferences and drivers of adoption for various drug delivery technologies in the U.S. pharmaceutical market.
Through interviews with both physicians and patients, Frost & Sullivan aims to identify key drivers and obstacles to adoption and utilization of various drug delivery technologies. Additionally, patient feedback will be obtained in terms of awareness, usage, and desired improvements of specific brands as determined by clients.
Frost & Sullivan seeks feedback on areas of interest to the industry for an in-depth look at these issues from respondents. Various new therapeutic areas and treatment settings are being evaluated. The final decision for this new project will be based on market demand and shaped to meet the needs of the industry.
If you are interested in partnering with us, shaping, or obtaining the research for the study U.S. Drug Delivery Voice of the Customer 2008, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com with the following information: your full name, company name, title, telephone number, email address, city, state and country.
“Understanding how patients and prescribers view drug delivery methods as part of treatment is vital to drug developers throughout the industry,” notes Frost & Sullivan Industry Manager Daniel Ruppar. “Especially as companies evaluate new delivery opportunities, understanding how different technologies are viewed may lead to new product pathways not previously considered.”
While there are numerous types of drug delivery technologies available in terms of approved drugs for a disease, physician and patient decision factors are often the primary determinant of drug choice. This can especially impact drugs using device-driven drug delivery, or the success of new first-in-class products with novel delivery approaches.
“Developers that can better understand the drivers and obstacles of adoption and utilization preferences for pharmaceutical drug delivery can develop and refine their technologies to best serve patients and the medical community,” says Ruppar. “This can also drive decision factors for both lifecycle management activities and R&D programs.”
U.S. Drug Delivery Voice of the Customer 2008 is part of ongoing research conducted within the Pharmaceutical and Biotechnology Subscription, which also includes research in the following markets: Contract Research & Manufacturing, Biopharmaceuticals, Specialty Pharmaceuticals, Vaccines and Drug Delivery. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting, and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates, and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses, and the investment community from more than 30 offices on six continents.